Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 8 recruiting now early-phase tilt small index

Neurogenic Bladder: early-phase trial registry

8 of 17 indexed Neurogenic Bladder trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,004 of 28,707 conditions by registered trial count.

17 US clinical trials · 8 currently recruiting · #1,004 of 28,707 conditions by registered trial count

Neurogenic Bladder: 17 US clinical trials tracked, 8 recruiting.

Neurogenic Bladder is the subject of 17 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Medstar Health Research Institute, running 5 of these trials.

Enrollment posture brief

Registry condition neurogenic-bladder

OPEN 8 | RECR 47% | LATE 1 | EARLY 5 | RANK #1004 | SPON 5

Nearest open-share peer: Bone Loss (47% recruiting · 17 trials)

Acute Myeloid Leukemia, in R70.6%Abdominal Aortic Aneurysm52.9%Neurogenic Bladder (this)47%Acute Lymphoblastic Leukemia23.5%Actinic Keratosis11.8%
Open-enrollment share among volume-matched conditions near Neurogenic Bladder

Neurogenic Bladder lists 8 open slots (47% of 17 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Neurogenic Bladder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Neurogenic Bladder recruits in line with its size-band peers.

    8 of 17 indexed trials (47.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Neurogenic Bladder research.

    Medstar Health Research Institute accounts for 5 of 17 trials (29.4%). 12 distinct sponsors appear on at least one study for this condition label.

  3. Most Neurogenic Bladder trials plan to enrol fewer than 100 people.

    Median target enrolment is 50 among the 17 trials that report a genuine target (sentinel values excluded). 13 of those (76.5%) plan for fewer than 100 participants.

  4. Neurogenic Bladder research is mostly interventional.

    12 interventional and 5 observational studies make up this index (70.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 22Phase 41

Open and recent trials

17 total, page 1 of 1

RECRUITING Phase 2 182 participants

Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters

Medstar Health Research Institute

NCT04323735

RECRUITING Phase 2 120 participants

Intravesical LGG VS Saline Bladder Wash RCT

Medstar Health Research Institute

NCT05230511

RECRUITING NA 70 participants

Effect of Chlorhexidine Gluconate Bladder Instillations in Patients With Chronic Suprapubic Catheters on Unplanned Healthcare Encounters and Quality of Life

Yale University

NCT06163469

RECRUITING 60 participants

Patient and Caregiver Perspectives on Intravesical Instillations for Urinary Symptoms

Medstar Health Research Institute

NCT07390591

RECRUITING Early Phase 1 40 participants

Intravesical Lactobacillus Crispatus: Clinical Safety and Microbiome Evaluation

Medstar Health Research Institute

NCT07308808

RECRUITING Early Phase 1 30 participants

Concomitant Renal and Urinary Bladder Allograft Transplantation

Mayo Clinic

NCT04626167

RECRUITING NA 29 participants

Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS

The Methodist Hospital Research Institute

NCT06072703

RECRUITING NA 5 participants

Vascularized Composite Bladder Allograft Transplantation

University of Southern California

NCT05462561

ACTIVE NOT RECRUITING 600 participants

Continence Care Registry

Hollister Incorporated

NCT04924569

ACTIVE NOT RECRUITING 75 participants

Qualitative Assessment of the Impact of TTNS on QOL and Participation

Medstar Health Research Institute

NCT04248322

ACTIVE NOT RECRUITING NA 10 participants

Electrical Stimulation for Continence After Spinal Cord Injury

Palo Alto Veterans Institute for Research

NCT02978638

ACTIVE NOT RECRUITING 6 participants

Pediatric Locomotor Training Bladder Study

University of Louisville

NCT03559036

COMPLETED NA 126 participants

Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE "CONTINENCE" Clinical Study

SpineX

NCT05301335

COMPLETED Phase 4 52 participants

Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder

AbbVie

NCT01192568

COMPLETED NA 50 participants

Reducing Anticholinergic Bladder Medication Use in Spinal Cord Injury With Home Neuromodulation

The University of Texas Health Science Center, Houston

NCT04074616

COMPLETED Early Phase 1 20 participants

Treatment of Spinal Cord Injury Patients for Neurogenic Bladder: Anticholinergic Agent vs. Mirabegron

The University of Texas Health Science Center at San Antonio

NCT03612401

COMPLETED 12 participants

Central Nervous System Changes Following OnabotulinumtoxinA Injection in the Bladder

The Methodist Hospital Research Institute

NCT03033355

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 2
Phase 4 1

Named interventions

Most-linked intervention names on Neurogenic Bladder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Intra-detrusor injection of Onabotulinumtoxin-A Drug
1 trials
SCONE Device
1 trials
Low dose Device
1 trials
High Dose Device
1 trials
Finetech Vocare Bladder System Device
1 trials
Locomotor Training Procedure
1 trials
Semi-structured interview Behavioral
1 trials
Culturelle 10 Billion CFU Capsule Drug
1 trials

US sites by state

Facility locations filed on Neurogenic Bladder trials. A trial with sites in several states counts in each.

Texas 5 trials
California 4 trials
New York 2 trials
North Carolina 2 trials
Minnesota 2 trials
Georgia 2 trials
Colorado 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Neurogenic Bladder page

17 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neurogenic Bladder condition card totals 17 registered trials; most-linked intervention Intra-detrusor injection of Onabotulinumtoxin-A; top US site state District of Columbia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.